US23283X2062
© PR Newswire
10.12.2025
CTSO
LISTED
NASDAQ
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
News Preview
PRINCETON, N.J., Dec. 10, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO, will join Jason Kolbert, Head of Healthcare Research at D. B...
Themefolio
Profiler
Peergroup
© PR Newswire
17.11.2025
CTSO
LISTED
NASDAQ
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
News Preview
PRINCETON, N.J., Nov. 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investo...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2025
CTSO
LISTED
NASDAQ
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Third quarter 2025 revenue of $9.5 million, up 10% year-over-year
Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with an additional $2.5 million of cash, and extends the interest only-period thro...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
11.11.2025
CTSO
LISTED
NASDAQ
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
News Preview
PRINCETON, N.J., Nov. 11, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer,...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
30.10.2025
CTSO
LISTED
NASDAQ
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
PRINCETON, N.J., Oct. 30, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2025
CTSO
LISTED
NASDAQ
In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
News Preview
PRINCETON, N.J., Oct. 28, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, honors the life and legacy of Dr. Robert Hawes Bartlett, MD (1939-2025), the company's former Ch...
Themefolio
Profiler
Peergroup
© PR Newswire
29.09.2025
CTSO
LISTED
NASDAQ
CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
News Preview
PRINCETON, N.J., Sept. 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today its strong scientific presence at the upcoming European Association for Cardio-...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
CTSO
LISTED
NASDAQ
CytoSorbents Provides DrugSorb-ATR Regulatory Update
News Preview
PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today provided a regulatory update on DrugSorb™-ATR....
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
CTSO
LISTED
NASDAQ
CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
PRINCETON, N.J., Sept. 5, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the H.C. Wainwright 27th Ann...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
CTSO
LISTED
NASDAQ
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
News Preview
FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization
PRINCETON, N.J., Aug. 20, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac s...
Themefolio
Profiler
Peergroup
© PR Newswire
07.08.2025
CTSO
LISTED
NASDAQ
CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update
News Preview
PRINCETON, N.J., Aug. 7, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2025, and recent business highlights. ...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
CTSO
LISTED
NASDAQ
CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights
News Preview
PRINCETON, N.J., July 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2025 financial results and recent business highlights after the market close on Thursday, August 7, 202...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
02.07.2025
CTSO
LISTED
NASDAQ
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
News Preview
PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and Heal...
Themefolio
Profiler
Peergroup
© PR Newswire
24.06.2025
CTSO
LISTED
NASDAQ
CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR
News Preview
PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Dr...
Themefolio
Profiler
Peergroup
© PR Newswire
29.05.2025
CTSO
LISTED
NASDAQ
CytoSorbents to Participate at the Jefferies Global Healthcare Conference
News Preview
PRINCETON, N.J., May 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthca...
Themefolio
Profiler
Peergroup
© PR Newswire
22.05.2025
CTSO
LISTED
NASDAQ
CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
News Preview
Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy
PRINCETON, N.J., May 22, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care u...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
CTSO
LISTED
NASDAQ
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2025, and recent business highlights. ...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2025
CTSO
LISTED
NASDAQ
CytoSorbents Provides Regulatory Update for DrugSorb-ATR
News Preview
PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device. DrugSorb-ATR is designed to reduce the severit...
Themefolio
Profiler
Peergroup
© PR Newswire
29.04.2025
CTSO
LISTED
NASDAQ
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights
News Preview
PRINCETON, N.J., April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
21.04.2025
CTSO
LISTED
NASDAQ
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
News Preview
PRINCETON, N.J., April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss...
Themefolio
Profiler
Peergroup
© PR Newswire
17.04.2025
CTSO
LISTED
NASDAQ
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller
News Preview
Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies
Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensi...
Themefolio
Profiler
Peergroup
© PR Newswire
14.04.2025
CTSO
LISTED
NASDAQ
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
News Preview
PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. With anticipated marketing ap...
Themefolio
Profiler
Peergroup
© PR Newswire
04.04.2025
CTSO
LISTED
NASDAQ
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
News Preview
PRINCETON, N.J., April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of the expiration date of the Series B Right Warrants (the "Series B Right Warrants") issued in the Compan...
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
CTSO
LISTED
NASDAQ
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
News Preview
2024 marked by strong commercial execution and improved operating leverageCompany continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheetStrengthening of clinical portfolio across cardiac surgery and critical care in 20...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
CTSO
LISTED
NASDAQ
CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit
News Preview
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025
PRINCETON, N.J., March 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threa...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.03.2025
CTSO
LISTED
NASDAQ
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
News Preview
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
CTSO
LISTED
NASDAQ
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
News Preview
CytoSorbents' Preliminary Unaudited Q4 2024 Product Revenue Increased 22-25% From A Year Ago With Product Gross Margins Of ~70%...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
CTSO
LISTED
NASDAQ
CytoSorbents Announces Rights Offering
News Preview
CytoSorbents Announces Rights Offering Exclusive to Stockholders Who Hold or Have Bought CTSO Common Stock by Market Close on Friday, December 13, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2024
CTSO
LISTED
NASDAQ
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
News Preview
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that the Dr. Phillip Chan, Chief Executive Officer, and Pete...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.08.2024
CTSO
LISTED
NASDAQ
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
PRINCETON, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it granted inducement equity awards on August 14, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2024
CTSO
LISTED
NASDAQ
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
News Preview
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2024
CTSO
LISTED
NASDAQ
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
News Preview
CytoSorbents CFO Kathleen P. Bloch Retires CytoSorbents CFO Kathleen P. Bloch Retires...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2024
CTSO
LISTED
NASDAQ
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
News Preview
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
CTSO
LISTED
NASDAQ
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
News Preview
CytoSorbents CEO Dr. Phillip Chan to highlight its innovative critical care and cardiac surgery blood purification therapy at AAPI Conference this weekend...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
CTSO
LISTED
NASDAQ
CytoSorbents Secures $20 Million Credit Facility
News Preview
$20 million credit facility provides CytoSorbents with important non-dilutive capital to support its regulatory and commercialization objectives...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
CTSO
LISTED
NASDAQ
CytoSorbents 公司宣布 CytoSorb® 獲得台灣監管部門批准
News Preview
當地是全球最先進的醫療保健系統之一，現在引進這個迄今應用於 75 個國家近 25 萬次治療的強大的血液淨化技術，用於治療危疾和心臟手術患者 當地是全球最先進的醫療保健系統之一，現在引進這個迄今應用於 75 個國家近 25 萬次治療的強大的血液淨化技術，用於治療危疾和心臟手術患者...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2024
CTSO
LISTED
NASDAQ
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
News Preview
CTSO STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
CTSO
LISTED
NASDAQ
CytoSorbents Reports First Quarter 2024 Results
News Preview
CytoSorbents Reports First Quarter 2024 Results...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
